How a new drug prototype regenerates lung tissue
A new study from Scripps Research and Calibr-Skaggs scientists provides pharmacological proof of concept for an upcoming phase 1 clinical trial. LA JOLLA, CA — Pulmonary diseases are a leading cause of morbidity and mortality worldwide. For many progressive lung diseases like idiopathic pulmonary fibrosis (IPF), a key issue is a low supply of new stem cells to repair and reverse damage. These cells are responsible for regenerating and increasing the growth of healthy tissue — without them, lung function